FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Madrigal Pharmaceuticals, Inc. Stock AnalysisComprehensive stock analysis for Madrigal Pharmaceuticals, Inc. (MDGL) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMDGL
MDGL
Madrigal Pharmaceuticals, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
MDGL
Home🔹Stocks🔹Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

MDGL•NASDAQ

Madrigal Pharmaceuticals, Inc.

MDGL•NASDAQ
Market cap
$12.42B
Sentiment

Your view on MDGL

Mkt Cap
$12.42B
Sentiment
Your view
MDGL
Madrigal Pharmaceuticals, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
MDGL
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Madrigal Pharmaceuticals, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
William J. Sibold
Headquarters
Four Tower Bridge, West Conshohocken, PA, US
Industry
Biotechnology
Sector
Healthcare
CEO
William J. Sibold
Headquarters
Four Tower Bridge, West Conshohocken, PA, US
Description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News